These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21212603)

  • 1. Predicting the severity of acute urinary toxicity after brachytherapy with iodine-125 for localized prostate cancer.
    Takeda K; Jingu K; Koto M; Fujimoto K; Narazaki K; Kubozono M; Saito H; Yamada S; Mitsuduka K; Ishidoya S; Ariga H; Arai Y; Yamada S
    Tohoku J Exp Med; 2011 Jan; 223(1):55-60. PubMed ID: 21212603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
    Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up.
    Keyes M; Miller S; Moravan V; Pickles T; Liu M; Spadinger I; Lapointe V; Morris WJ
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):649-55. PubMed ID: 19211199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
    Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
    Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of urinary symptoms after 125iodine prostate brachytherapy.
    Kelly K; Swindell R; Routledge J; Burns M; Logue JP; Wylie JP
    Clin Oncol (R Coll Radiol); 2006 May; 18(4):326-32. PubMed ID: 16703751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary symptom flare following I-125 prostate brachytherapy.
    Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
    BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study.
    Henderson A; Ismail AK; Cunningham M; Aldridge S; Loverock L; Langley SE; Laing RW
    Clin Oncol (R Coll Radiol); 2004 Apr; 16(2):95-104. PubMed ID: 15074730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.
    Thomas C; Keyes M; Liu M; Moravan V
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):447-55. PubMed ID: 18395357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation.
    Le Fur E; Malhaire JP; Nowak E; Rousseau B; Erauso A; Pene-Baverez D; Papin G; Delage F; Perrouin-Verbe MA; Fournier G; Pradier O; Valeri A
    Brachytherapy; 2013; 12(6):589-95. PubMed ID: 23669150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.
    Hathout L; Folkert MR; Kollmeier MA; Yamada Y; Cohen GN; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):312-9. PubMed ID: 25304791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: a phase 2 study.
    Salem N; Simonian-Sauve M; Rosello R; Alzieu C; Gravis G; Maraninchi D; Bladou F
    Radiother Oncol; 2003 Feb; 66(2):159-65. PubMed ID: 12648787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method.
    Kang SK; Chou RH; Dodge RK; Clough RW; Kang HL; Bowen MG; Steffey BA; Das SK; Zhou SM; Whitehurst AW; Buckley NJ; Kim JH; Joyner RE; Sarmina I; Montana GS; Ingram SS; Anscher MS
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):937-45. PubMed ID: 11429221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
    Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Factors for Prolonged Urination Disorder After Permanent
    Mori H; Fukumori T; Daizumoto K; Tsuda M; Kusuhara Y; Fukawa T; Yamamoto Y; Yamaguchi K; Takahashi M; Kubo A; Kawanaka T; Furutani S; Ikushima H; Kanayama HO
    In Vivo; 2017; 31(4):755-761. PubMed ID: 28652453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
    Mabjeesh NJ; Chen J; Stenger A; Matzkin H
    Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial changes of international prostate symptom score following I-125 prostate brachytherapy.
    Ohashi T; Yorozu A; Toya K; Saito S; Momma T
    Int J Clin Oncol; 2006 Aug; 11(4):320-5. PubMed ID: 16937307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.